HIV-1 gag 裂解位点突变对利托那韦增强的达芦那韦的病毒学应答的积极影响。
Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir.
机构信息
AP-HP, Groupe Hospitalier Bichat-Claude Bernard, Laboratoire de Virologie, 75018 Paris, France.
出版信息
Antimicrob Agents Chemother. 2011 Apr;55(4):1754-7. doi: 10.1128/AAC.01049-10. Epub 2011 Jan 31.
Abstract
We assessed the roles of baseline gag and gag-pol cleavage site mutations (CSM) on the virological outcome of a darunavir-based regimen in highly antiretroviral-experienced patients. We showed the association, in multivariate analysis, between the A431V gag CSM and the virological response, defined as a reduction in plasma HIV-1 RNA to <50 copies/ml at month 3 (P = 0.028). Our results suggest that a specific gag CSM might have a role on protease inhibitor susceptibility in an inhibitor-specific manner.
摘要
我们评估了基于达芦那韦的方案中基线 gag 和 gag-pol 切割位点突变（CSM）对高度抗逆转录病毒经验患者病毒学结果的作用。我们在多变量分析中表明， gag CSM 的 A431V 与病毒学应答之间存在关联，定义为在第 3 个月时血浆 HIV-1 RNA 减少到<50 拷贝/ml（P=0.028）。我们的结果表明，特定的 gag CSM 可能以抑制剂特异性方式对蛋白酶抑制剂的敏感性起作用。
相似文献
1
Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir.HIV-1 gag 裂解位点突变对利托那韦增强的达芦那韦的病毒学应答的积极影响。
Antimicrob Agents Chemother. 2011 Apr;55(4):1754-7. doi: 10.1128/AAC.01049-10. Epub 2011 Jan 31.
2
Darunavir: a review of its use in the management of HIV infection in adults.地瑞那韦：关于其在成人HIV感染管理中应用的综述
Drugs. 2009;69(4):477-503. doi: 10.2165/00003495-200969040-00007.
3
Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.在感染HIV-1且有蛋白酶抑制剂使用经验的患者中，与对达芦那韦/利托那韦的病毒学反应相关的突变
J Antimicrob Chemother. 2009 Mar;63(3):585-92. doi: 10.1093/jac/dkn544. Epub 2009 Jan 15.
4
5
Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen.HIV-1 非 B 亚型 gag 基因切割位点多态性与一线洛匹那韦/利托那韦单药方案的病毒学结局。
PLoS One. 2011;6(9):e24798. doi: 10.1371/journal.pone.0024798. Epub 2011 Sep 20.
6
Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2.基线病毒易感性对达芦那韦/利托那韦与对照蛋白酶抑制剂治疗既往接受过治疗的1型HIV感染患者疗效的影响：POWER 1和POWER 2研究。
AIDS Res Hum Retroviruses. 2008 Oct;24(10):1275-80. doi: 10.1089/aid.2007.0275.
7
Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.在接受达芦那韦/利托那韦单药治疗的患者中很少观察到耐药少数物种。
J Antimicrob Chemother. 2012 Jun;67(6):1470-4. doi: 10.1093/jac/dks052. Epub 2012 Mar 5.
8
HIV-1 Gag mutations alone are sufficient to reduce darunavir susceptibility during virological failure to boosted PI therapy.仅 HIV-1 Gag 突变就足以降低强化蛋白酶抑制剂治疗病毒学失败时对达芦那韦的敏感性。
J Antimicrob Chemother. 2020 Sep 1;75(9):2535-2546. doi: 10.1093/jac/dkaa228.
9
Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients. gag 突变可能会影响初治 HIV 感染患者接受双重增强蛋白酶抑制剂联合治疗的病毒学应答。
Antimicrob Agents Chemother. 2010 Jul;54(7):2910-9. doi: 10.1128/AAC.00194-10. Epub 2010 May 3.
10
Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients. gag 基因决定因素对接受含洛匹那韦增效剂方案治疗的 HIV-2 感染者病毒学结局的影响。
AIDS. 2013 Jan 2;27(1):69-80. doi: 10.1097/QAD.0b013e32835a10d8.
引用本文的文献
1
Modulation of HIV-1 Gag/Gag-Pol frameshifting by tRNA abundance.tRNA 丰度对 HIV-1 Gag/Gag-Pol 框移的调控。
Nucleic Acids Res. 2019 Jun 4;47(10):5210-5222. doi: 10.1093/nar/gkz202.
2
Resistance mutations outside the integrase coding region have an effect on human immunodeficiency virus replicative fitness but do not affect its susceptibility to integrase strand transfer inhibitors.整合酶编码区以外的耐药突变会影响人类免疫缺陷病毒的复制适应性，但不影响其对整合酶链转移抑制剂的敏感性。
PLoS One. 2013 Jun 11;8(6):e65631. doi: 10.1371/journal.pone.0065631. Print 2013.
3
Human Immunodeficiency Virus Gag and protease: partners in resistance.人类免疫缺陷病毒 Gag 和蛋白酶：耐药的伙伴。
Retrovirology. 2012 Aug 6;9:63. doi: 10.1186/1742-4690-9-63.
4
Comparison of drug resistance scores for tipranavir in protease inhibitor-naive patients infected with HIV-1 B and non-B subtypes.替诺福韦耐药评分在初治感染 HIV-1 B 和非 B 亚型的患者中的比较。
Antimicrob Agents Chemother. 2011 Nov;55(11):5362-6. doi: 10.1128/AAC.00611-11. Epub 2011 Aug 8.
5
Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of antiretroviral therapy.基于 3'Gag(p2/p7/p1/p6)/PR/RT/INT-重组病毒的新型方法，可同时定量测定对成熟、蛋白酶、逆转录酶和整合酶 HIV 抑制剂的表型耐药性：抗逆转录病毒治疗多靶点时代的有用工具。
Antimicrob Agents Chemother. 2011 Aug;55(8):3729-42. doi: 10.1128/AAC.00396-11. Epub 2011 May 31.
本文引用的文献
1
Gag mutations can impact virological response to dual-boosted protease inhibitor combinations in antiretroviral-naïve HIV-infected patients. gag 突变可能会影响初治 HIV 感染患者接受双重增强蛋白酶抑制剂联合治疗的病毒学应答。
Antimicrob Agents Chemother. 2010 Jul;54(7):2910-9. doi: 10.1128/AAC.00194-10. Epub 2010 May 3.
2
Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance.1型人类免疫缺陷病毒蛋白酶相关切割位点突变增强抑制剂耐药性。
J Virol. 2009 Nov;83(21):11027-42. doi: 10.1128/JVI.00628-09. Epub 2009 Aug 12.
3
Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1.1型人类免疫缺陷病毒蛋白酶抑制剂耐药株中与适应性和药物敏感性相关的Gag决定簇
J Virol. 2009 Sep;83(18):9094-101. doi: 10.1128/JVI.02356-08. Epub 2009 Jul 8.
4
Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.除了补偿适应性损失外，Gag突变在高度耐药的患者中对HIV-1对蛋白酶抑制剂的耐药性有很大影响。
PLoS Pathog. 2009 Mar;5(3):e1000345. doi: 10.1371/journal.ppat.1000345. Epub 2009 Mar 20.
5
Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients.在感染HIV-1且有蛋白酶抑制剂使用经验的患者中，与对达芦那韦/利托那韦的病毒学反应相关的突变
J Antimicrob Chemother. 2009 Mar;63(3):585-92. doi: 10.1093/jac/dkn544. Epub 2009 Jan 15.
6
Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease.gag突变对HIV-1蛋白酶中达芦那韦耐药性突变选择的影响。
J Antimicrob Chemother. 2008 Nov;62(5):905-8. doi: 10.1093/jac/dkn338. Epub 2008 Sep 1.
7
A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.一种基于底物的新型HIV-1蛋白酶抑制剂耐药机制。
PLoS Med. 2007 Jan;4(1):e36. doi: 10.1371/journal.pmed.0040036.
8
Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.HIV-1 治疗患者中 Gag 裂解位点与蛋白酶突变及病毒学反应的关联
J Infect. 2007 Apr;54(4):367-74. doi: 10.1016/j.jinf.2006.06.012. Epub 2006 Jul 26.
9
Co-evolution of nelfinavir-resistant HIV-1 protease and the p1-p6 substrate.奈非那韦耐药性HIV-1蛋白酶与p1-p6底物的共同进化
Virology. 2006 Apr 10;347(2):405-9. doi: 10.1016/j.virol.2005.11.049. Epub 2006 Jan 20.
10
Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease.1型人类免疫缺陷病毒核衣壳-p1裂解位点与病毒蛋白酶中V82A耐药突变协同进化的结构基础
J Virol. 2004 Nov;78(22):12446-54. doi: 10.1128/JVI.78.22.12446-12454.2004.
Zotero 插件